La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)--Mar. 23, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing of an underwritten public offering of approximately 3.7 million shares of common stock, offered at a price of $33.50 per share, for gross proceeds of $125 million. In addition, La Jolla has granted the underwriters a 30-day option to purchase up to an additional 559,700 shares of common stock.

The offering is expected to close on or about March 28, 2017, subject to customary closing conditions.

La Jolla intends to use the net proceeds from the offering for general corporate purposes, including funding its ongoing and future clinical trials of its drug candidates, expenses relating to the potential regulatory approval of LJPC-501, potential future acquisitions, and general and administrative expenses.

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey, Chardan, and LifeSci Capital LLC are acting as lead managers for the offering.

The shares of La Jolla common stock described above are being offered only by means of a prospectus supplement and related prospectus pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. Copies of the final prospectus supplement, when available, and related prospectus relating to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204, or from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by calling 631-274-2806, or by faxing 631-254-7140.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The company has several product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of synthetic human angiotensin II for the potential treatment of catecholamine resistant hypotension. LJPC-401 is La Jolla’s proprietary formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is La Jolla’s next-generation gentamicin derivative program that is focused on the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Forward Looking Statements

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current expectations and beliefs, speak only as of the date of this press release and involve risks and uncertainties, many of which are outside of our control, that can cause actual results to differ materially from those anticipated in the forward-looking statements. Potential risks and uncertainties include, but are not limited to: the closing of the public offering, the intended use of the net proceeds raised during the public offering, and the expected duration of the Company’s operating runway based on current cash resources. Further information regarding these and other risks that could affect our future results of operations are included in La Jolla’s most recently filed Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as filed with the U.S. Securities and Exchange Commission at We disclaim any intent to update any forward-looking statements to reflect actual events that occur after the date of this press release.

Source: La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company
Sandra Vedrick
Associate Director, Investor Relations & Human Resources
Phone: 858-256-7910
Dennis M. Mulroy
Chief Financial Officer
Phone: 858-433-6839